

Artificial Intelligence: impact on Health Systems

Yolande Lievens, MD, PhD Ghent University Hospital & Ghent University







What is a health system?

How to generate impact for the health system?


What is the impact of artificial intelligence on the health system? On the radiation oncology system?


How can we embed artificial intelligence in the health system?






A health (care) system is an organisation of people, institutions, and resources that delivers health care services to meet the health needs of target populations.









Rifat Atun. Building a High Value Health System

challenge: rapidly converging contextual transitions



impact



efficiency



Cost-Effectiveness

Cost new - Cost old

Outcome new - Outcome old

Value

Health Outcomes that matter to *patients*

Costs

of delivering these outcomes

building blocks

Leadership/governance


Health care financing

Health workforce


Medical products, technologies

Information and research


Service delivery



applications of AI in health care



applications of AI in radiation oncology






A Preliminary Experience of Implementing Deep-Learning Based Auto-Segmentation in Head and Neck Cancer: A Study on Real-World Clinical Cases

Yang Zhong^{1,2,3†}, Yanju Yang^{1,2,3†}, Yingtao Fang^{1,2,3}, Jiazhou Wang^{1,2,3*} and Weigang Hu^{1,2,3*}

substantial decrease in delineation time




OPEN ACCESS


Physics Contribution

Generating High-Quality Lymph Node Clinical Target Volumes for Head and Neck Cancer Radiation Therapy Using a Fully Automated Deep Learning-Based Approach

Carlos E. Cardenas, PhD,* Beth M. Beadle, MD, PhD,†
Adam S. Garden, MD,‡ Heath D. Skinner, MD, PhD,
Jinzhong Yang, PhD,* Dong Joo Rhee, MS,* Rachel E. McCarroll, PhD,
Tucker J. Netherton, DMP,* Skylar S. Gay, BS,* Lifei Zhang, PhD,*
and Laurence E. Court, PhD*



IJROBP 2020



Reviewer 1 Ia-V right 25 0 Ia-V left 25 0	3 0 0 0 0	Sc 1 4 7	ores 2	3
Reviewer 1 Ia-V right 25 0 Ia-V left 25 0	0 0 0	4		3
Ia-V right 25 0 Ia-V left 25 0	0		3	
Ia-V left 25 0	0		3	
	0	7		0
Ib-V right 25 0			0	0
10- V Hght 25	0	4	3	0
Ib-V left 25 0	U	7	0	0
II-IV right 25 0	0	4	3	0
II-IV left 25 0	0	7	0	0
RP right 25 0	0	7	0	0
RP left 25 0	0	7	0	0
Reviewer 2				
Ia-V right 14 11	0	4	3	0
Ia-V left 14 11	0	4	3	0
Ib-V right 14 11	0	4	3	0
Ib-V left 14 11	0	4	3	0
II-IV right 14 11	0	4	3	0
II-IV left 14 11	0	4	3	0
RP right 21 4	0	5	2	0
RP left 21 4	0	5	2 2	0
Reviewer 3				
Ia-V right 0 25	0	0	5	2
Ia-V left 0 24	1	0	7	0
Ib-V right 0 25	0	0	5	2
Ib-V left 1 23	1	0	7	0
II-IV right 2 23	0	0	6	1
II-IV left 4 21	0	1	6	0
RP right 9 16	0	1	6	0
	0	2	5	0

Individual cases were reviewed on a slice-by-slice basis by 3 radiation oncologists each having more than 10 years of HNC experience.

Auto-segmentation scores: 1 = clinically acceptable without requiring edits; 2 = requiring minor edits (ie, stylistic recommendations, <2 minutes); 3 = requiring major edits.

Abbreviation: HNC = head and neck cancer.

remaining yet variable need for human interaction

Cardenas et al, IJROBP 2022






Article

Enhancing Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer Patients with iCE, a Novel System for Automated Multi-Criterial Treatment Planning Including Beam Angle Optimization

Kristine Fjellanger ^{1,2,*}, Liv Bolstad Hysing ^{1,2}, Ben J. M. Heijmen ³, Helge Egil Seime Pettersen ¹, Inger Marie Sandvik ¹, Turid Husevåg Sulen ¹, Sebastiaan Breedveld ³ and Linda Rossi ³

Manual plans: 2 - 4h (<1h to full day) Automated plans: less than 10min



Fjellanger et al, Cancers 2020

To date: increased **efficiency in the radiation treatment planning process** most evident Ideally, a system that

- accurately identifies both normal and target volumes,
- estimates the optimal modality and beam arrangement,
- achieves deliverable plans that maximize TCP and minimize risk of toxicity,
- integrates clinically relevant data from multiple sources (e.g. EHR, imaging data) to further tailor the treatment approach.


As such:

speed-up the process, **reduce** the time burden of human intervention, allow for a **shorter** interval from simulation to initiation of treatment, and **facilitate paradigm shifts** such as online adaptive planning.

at least similar outcomes

lower resource time, lower cost?


applications of Al in RO, cost impact?




Courtesy Defourny Noémie, 2019


impact on costs?















75% clinically acceptable without manual fine-tuning, yet still requires human input and validation

average optimization time -77.3% minor impact on total cost -3,6%

Vanderstraeten B et al, IJROBP 2018

impact on costs?







opportunities for the radiation oncology workforce

a MEMBERSHIP ORGANISATION FIGHTING CANCER TOGETHER	High-income countries	Upper-middle- income countries	Lower- middle- income countries	Low-income counties			
Fractions	76 424 000	77 014 000	40 974 000	13 268 000			
>200,000 radiation oncology professionals worldwide!							
Radiation oncologists to be trained	15500	16800	9900	3300			
Medical physicists to be trained	17 200	12 500	7200	2400			
Radiation technologists to be trained	51900	45300	24900	8100			


the health workforce, reduced time needs




the radiation oncology workforce, task shifting




the radiation oncology workforce, task shifting



the health workforce, task shifting




sustainability of Al systems



integration of AI in clinical workflow


- → development of the algorithms
- → additional QA and maintenance demands accuracy of 4 months half-life continuous adaptation and learning

sustainability of Al systems



challenges


- Human barriers to Al adoption in healthcare;
- Developing a better understanding of interaction between human and algorithm;
- Algorithmic interpretability and explainability.
- Logistical difficulties in implementing Al systems
- Achieving robust regulation and rigorous quality control;
- Susceptibility to adversarial attack or manipulation;
- Dataset shift;
- Accidentally fitting confounders versus true signal;
- Challenges in generalisation to new populations and settings;
- Algorithmic, discriminatory bias.




- Promote population-representative data with accessibility, standardization, and quality is imperative.
- Prioritize ethical, equitable, and inclusive health care AI while addressing explicit and implicit bias.
- Near-term focus is needed on augmented intelligence vs Al autonomous agents.
- Develop and deploy appropriate training and educational programs to support health care AI.
- Leverage frameworks and best practices for learning health care systems, human factors, and implementation science to address the challenges in operationalizing health care AI.
- Balance innovation with safety via regulation and legislation to promote trust.

where do we stand in terms of impact?

- limited number of models trained on prospective data
- almost no (randomised) clinical trials, using clinical outcomes as trial endpoints to demonstrate longer-term benefit
- limited understanding about the breadth and effectiveness of AI in radiotherapy, with difficulty comparing different algorithms
- metrics used do not necessarily reflect clinical applicability
- limited number of cost analyses
- barely any cost-effectiveness data






achievable outcome

achieved outcome

dedicated trials



Key

Blue boxes: standard manual pathway; Red boxes: fully automated pathway;

Green box: manual contours and automated plan

CTV – Clinical target volumes – areas of microscopic disease

GTV – Gross tumour volume – Visible tumour OARS – Organs at risk of radiation damage

ARCHERY ex. of prospective clinical trial outcome & cost of Al in LMIC


Courtesy Ajay Aggarwal

ESTRO HERO

better understanding the value


Health Outcomes that matter to *patients*

Costs of delivering these outcomes



Value-Based Framework for Radiation Oncology

inclusion in reimbursement system?



COMINU COMMISSION Lancet Oncology Groundshot Commission

"Technological advances do have a part to play in future European cancer research and control efforts, but they must be part of an ecosystem that delivers advances that are patient centred, effective, affordable and equitable, across the spectrum of site-specific cancers, cancer control disciplines and research domains."

launch 16th November 2022

THE LANCET The best science for better lives







